Pharma has a new innovation mythology: that you can build a durable patent moat by spending as little as possible, filing sparingly, and letting the calendar do the heavy lifting.
Its a tempting storyespecially after years of margin pressure. But the r…
The Safe Patent Portfolio Trap: Why Minimal Filing Costs Pharma a Decade of Growth Read Post »
A single paragraph can cost a generic drugmaker $50 million.
Thats not a metaphor. Its the kind of paper cut that turns into a cash woundafter a Paragraph IV filing triggers a patent dispute, and one badly drafted passage ends up being treated like a r…
At-risk launches arent a gamble anymoretheyre a math problem.
In pharma, the phrase at risk has long carried a hint of romantic defiance: a company ships product knowing litigation is unresolved, accepting that damagesor even an injunctioncould follow….
The At-Risk Launch: When the Math Says Go, Even If the Court Says No Read Post »
Ever wonder why a handful of new drug patents can seem to stretch an entire decade? The story youre often told is neat: follow-on innovation improves outcomes, competition arrives when the science is ready.
But the realityespecially in periods leadin…
The Evergreening Myth: How to Spot the Cracks in a 20-Patent Thicket Read Post »
Most pharma patent challenges are treated like a last resort. Thats a mistake.
Heres the uncomfortable truth: when a method of use patent is weak, waiting to attack it is usually the most expensive optioneven if you ultimately win.
In a recent DrugPate…
Sue Early, Win Big: The Hidden ROI of Challenging Weak Method-of-Use Drug Patents Read Post »
The 180-Day Exclusivity Trap: Why Being First Still Doesnt Pay
In generic drug markets, everyone talks about the 180-day exclusivity clockbecause it sounds like a straight line to pricing power, market share, and profits.
But the reality is more compli…
The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money Read Post »
Most companies treat patent settlements like a business-as-usual off-ramp. Thats a mistake. Heres the math behind why.
In pharma, weve all seen the playbook: a brand challenges a generic (or vice versa), litigation drags on, and somewhere along the way…
Your drugs patent fortress isnt as strong as it looksbecause device patents often crack first.
If you think the patent wars around pharmaceuticals are mainly battles over the active ingredientthe molecule, the formulation, the method-of-usethink again….
Why Device Patents Crack First: The Weakest Wall in Your Drug’s Patent Fortress Read Post »
The Salt Change Trap: When a New Patent Buys You Nothing (But Still Costs You Everything)
In drug development, the most expensive word isnt pipeline. Its exclusivity. And nowhere is that more visible than in the growing saga of the salt changea seeming…
The Salt Change Trap: When a New Patent Buys You Nothing Read Post »
Pediatric exclusivity was designed to protect children. But in practice, it can become a liability for everyone else in the drug ecosystempatients included.
Thats the central tension explored in a new piece from DrugPatentWatch: the six-month fuse mech…
The Six-Month Fuse: Why Pediatric Exclusivity Is a Liability, Not a Shield Read Post »
Get new actionable insights and updates from BiotechBlog
